Potency testing of veterinary vaccines: The way from in vivo to in vitro

Russell, 1959 1986, Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes, Off J Eur Communities, L358, 1 1986 Wilbur, 1996, The NIH test for potency, 360 Wunderli, 2003, Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice, Am J Vet Res, 64, 491, 10.2460/ajvr.2003.64.491 Servat, 2008, In vivo potency tests of rabies inactivated vaccines for veterinary use: a two year retrospective analysis of data according to the criteria of the European Pharmacopoeia, Pharmeuropa, Readers Tribune, 20, 655 Smith, 1973, A rapid reproducible test for determining rabies neutralizing antibody, Bull World Health Organ, 48, 535 Krämer, 2009, The rapid fluorescent focus inhibition test is a suitable method for batch potency testing of inactivated rabies vaccines, Biologicals, 37, 119, 10.1016/j.biologicals.2009.01.001 Krämer, 2010, Collaborative study for validation of a serological potency assay for rabies vaccine (inactivated) for veterinary use, Pharmeuropa Bio & Scientific Notes, 2, 37 2002 Rosskopf-Streicher, 1999, Potency testing of Swine erysipelas vaccines by serology results of a pre-validation study, ALTEX, 16, 123 Paul-Ehrlich-Institute, Validation of a serological method for the potency testing of erysipelas vaccines, Final Report BMBF Research Project No: 0311200, (1999) 57. 2004 1990 2011 2011 2011 Dietzschold, 1978, Structure and function of rabies virus glycoprotein, 1, Dev Biol Stand, 40, 45 2011 Maas, 2003, Correlation of haemagglutinin-neuraminidase and fusion protein content with protective antibody response after immunisation with inactivated Newcastle disease vaccines, Vaccine, 21, 3137, 10.1016/S0264-410X(03)00249-4 Claassen, 2003, Feasibility study to evaluate the correlation between results of a candidate in vitro assay and established in vivo assays for potency determination of Newcastle disease vaccines, Pharmeuropa Bio, 51 Claassen, 2004, Validation study to evaluate the reproducibility of a candidate in vitro potency assay of newcastle disease vaccines and to establish the suitability of a candidate biological reference preparation, Pharmeuropa Bio, 1 Jagt, 2010, The influence of the inactivating agent on the antigen content of inactivated Newcastle disease vaccines assessed by the in vitro potency test, Biologicals, 38, 128, 10.1016/j.biologicals.2009.07.006 De Mattia, 2011, The consistency approach for quality control of vaccines – A strategy to improve quality control and implement 3Rs, Biologicals, 39, 59, 10.1016/j.biologicals.2010.12.001 Grubman, 2010, Adenovirus serotype 5-vectored foot-and-mouth disease subunit vaccines: the first decade, Future Virol, 5, 51, 10.2217/fvl.09.68